JPRN-UMIN000011028CompletedPhase 2
Phase II, randomized, placebo-controlled study of docetaxel in combination with a mixed 20 peptides vaccine in patients with castration-resistant prostate cancer (CRPC) - Phase II study of docetaxel in combination with a mixed 20 peptide vaccine in patients with CRPC
Research Center for Innovative Cancer Therapy, Kurume University School of Medicine0 sites46 target enrollmentStarted: July 1, 2013Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 46
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- Male
Inclusion Criteria
- Not provided
Exclusion Criteria
- •The following patients must be excluded: 1. Patients who had received chemotherapy using docetaxel any time before the treatment. 2. Patients who had received pre-therapies including chemotherapy or immunotherapy within 28 days before the treatment. 3. Patients who had received radiotherapy or strontium-89 within the last 8 weeks before the treatment. 4. Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 5. Patients with active multiple cancers 6. Patients with the past history of severe allergic reactions. 7. Patients who do not agree with contraception during treatment and until 70 days after treatment. 8. Patients who had enrolled in another trial within 3 months or who are treating in another trial. 9. Patients who had received any peptides consist of a mixed 20 peptides (KRM-20). 10. Patients who are difficult to participate in this trial because of psychiatric symptoms. 11. Patients who are judged inappropriate for the clinical trial by doctors.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A Phase 2 study to evaluate safety and efficacy of Evinacumab in patients with severe hypertriglyceridemia at risk for acute pancreatitis.Severe Hypertriglyceridemia (sHTG)MedDRA version: 20.1Level: LLTClassification code 10020870Term: HypertriglyceridemiaSystem Organ Class: 100000004861EUCTR2016-003307-62-GBRegeneron Pharmaceuticals, Inc.50
Active, not recruiting
Phase 1
A clinical trial to test a new vaccine, in avoiding cytomegalovirus (CMV) infection after transplant, if you have never encountered the virus and your donor may harbor it.EUCTR2017-005047-32-NLHookipa Biotech AG150
Active, not recruiting
Phase 1
A clinical trial to test a new vaccine, in avoiding cytomegalovirus (CMV) infection after transplant, if you have never encountered the virus and your donor may harbor it.EUCTR2017-005047-32-ATHookipa Biotech GmbH150
Active, not recruiting
Phase 1
A clinical trial to test a new vaccine, in avoiding cytomegalovirus (CMV) infection after transplant, if you have never encountered the virus and your donor may harbor it.Prevention of clinically significant cytomegalovirus (CMV) infectionMedDRA version: 21.1Level: PTClassification code 10072247Term: Cytomegalovirus immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2017-005047-32-DKHookipa Biotech GmbH150
Active, not recruiting
Phase 1
A clinical trial to test a new vaccine, in avoiding cytomegalovirus (CMV) infection after transplant, if you have never encountered the virus and your donor may harbor it.Prevention of clinically significant cytomegalovirus (CMV) infectionMedDRA version: 21.1Level: PTClassification code 10072247Term: Cytomegalovirus immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2017-005047-32-DEHookipa Biotech GmbH150